NasdaqGS - Nasdaq Real Time Price USD

Cullinan Therapeutics, Inc. (CGEM)

7.71
+0.21
+(2.80%)
At close: May 19 at 4:00:01 PM EDT
7.71
0.00
(0.00%)
After hours: May 19 at 4:08:59 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
18,943
Operating Expense
208,926
196,919
190,649
132,137
86,897
Operating Income
-208,926
-196,919
-190,649
-132,137
-67,954
Net Non Operating Interest Income Expense
30,547
29,660
21,627
6,611
477
Other Income Expense
-240
-199
-201
276,842
-8
Pretax Income
-178,619
-167,458
-169,223
151,316
-67,485
Tax Provision
--
117
-14,122
42,121
0
Net Income Common Stockholders
-178,736
-167,383
-153,162
111,214
-65,570
Diluted NI Available to Com Stockholders
-178,736
-167,383
-153,162
111,214
-65,570
Basic EPS
-2.77
-2.78
-3.21
2.46
-1.52
Diluted EPS
-2.77
-2.78
-3.21
2.38
-1.52
Basic Average Shares
57,744.50
53,771
41,550
45,164
43,077.33
Diluted Average Shares
57,744.50
53,771
41,550
46,640
43,077.33
Total Operating Income as Reported
-208,926
-196,919
-191,089
144,648
-67,954
Total Expenses
208,926
196,919
190,649
132,137
86,897
Net Income from Continuing & Discontinued Operation
-178,736
-167,383
-153,162
111,214
-65,570
Normalized Income
-178,736
-167,383
-152,758.74
-88,597.09
-65,570
Interest Income
30,547
29,660
21,627
6,611
477
Net Interest Income
30,547
29,660
21,627
6,611
477
EBIT
-208,926
-196,919
-190,649
-132,137
-67,954
EBITDA
-208,620
-196,613
-190,339
-132,044
-67,901
Reconciled Depreciation
306
306
310
93
53
Net Income from Continuing Operation Net Minority Interest
-178,736
-167,383
-153,162
111,214
-65,570
Total Unusual Items Excluding Goodwill
0
0
-440
276,785
0
Total Unusual Items
0
0
-440
276,785
0
Normalized EBITDA
-208,620
-196,613
-189,899
-408,829
-67,901
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
-36.74
76,973.91
0
12/31/2021 - 1/8/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DSGN Design Therapeutics, Inc.
3.5300
+0.57%
 
ORIC ORIC Pharmaceuticals, Inc.
5.14
+8.67%
 
OLMA Olema Pharmaceuticals, Inc.
4.8000
+1.91%
 
NUVL Nuvalent, Inc.
73.31
-0.01%
 
ERAS Erasca, Inc.
1.2300
-4.28%
 
IMCR Immunocore Holdings plc
31.00
+2.07%
 
STOK Stoke Therapeutics, Inc.
9.83
+0.72%
 
KYMR Kymera Therapeutics, Inc.
30.20
-0.17%
 
PRAX Praxis Precision Medicines, Inc.
37.35
+0.89%
 
REPL Replimune Group, Inc.
8.20
+4.46%